Vaccinia virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancer

Annals of Surgery

Volumn 256, Issue 3, 2012, Pages 437-445

  Gholami, Sepideh ^a   Chen, Chun Hao ^a   Lou, Emil ^b   De Brot, Marina ^a   Fujisawa, Sho ^a   Chen, Nanhai G ^c   Szalay, Aladar A ^d   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

GLV 1h153; metastatic triple negative breast cancer; oncolytic viral therapy; vaccinia virus

Indexed keywords

GLV 1H153; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN METASTASIS; BREAST METASTASIS; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VACCINIA VIRUS;

EID: 84865500690     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182654572     Document Type: Conference Paper

References (30)

1. Bauer KR, BrownM, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721-1728. (Pubitemid 46668532)
2. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and EndResults database. Cancer. 2007;110:876-884. (Pubitemid 47257667)
3. Liedtke C, Kiesel L. Current issues of targeted therapy in metastatic triplenegative breast cancer. Breast Care (Basel). 2011;6:234-239.
4. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434. (Pubitemid 47219710)
5. Mersin H, Yildirim E, Berberoglu U, et al. The prognostic importance of triple negative breast carcinoma. Breast. 2008;17:341-346.
6. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008;15:303-308.
7. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17:173-176.
8. Dawood S, Lei X, Litton JK, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer [published online ahead of print February 22, 2012]. Cancer. 2012. doi:10.1002/cncr.27434.
9. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
10. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638-2645.
11. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29-33.
12. De Giorgi U, Rosti G, Frassineti L, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol. 2007;18:202-203. (Pubitemid 46152527)
13. Gholami S, Haddad D, Chen CH, et al. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery. 2011;150:1040-1047.
14. Haddad D, Chen NG, Zhang Q, et al. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med. 2011;9:36.
15. Fenner F, Henderson DA, Arita I, et al. Smallpox Eradication. Geneva, Switzerland: World Health Organization; 1988.
16. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00794131?term= GLONC1& rank=2. Accessed June 26, 2012.
17. Zhang Q, Yu YA, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67:10038-10046. (Pubitemid 47621255)
18. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16:53-61.
19. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxanebased chemotherapy for locally recurrent ormetastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22:595-602.
20. ErikssonM, Guse K, Bauerschmitz G, et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24?/low cells. Mol Ther. 2007;15:2088-2093. (Pubitemid 350148923)
21. Dupressoir T, Vanacker JM, Cornelis JJ, et al. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. 1989;49:3203-3208. (Pubitemid 19162125)
22. McDonald CJ, Erlichman C, Ingle JN, et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat. 2006;99:177-184. (Pubitemid 44268265)
23. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2177-2185. (Pubitemid 28498004)
24. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhancedMHCclass I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98:6396-6401. (Pubitemid 32488248)
25. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 2005;12:647-654. (Pubitemid 40561503)
26. Wang J, Hu P, Zeng M, et al. Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol. 2012;40:757-763.
27. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00574977?term= viral+therapy+and+breast+cancer&rank=7. Accessed June 26, 2012.
28. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00625456?term= JX-594&rank=4. Accessed June 26, 2012.
29. Haddad D, Chen N, Zhang Q, et al. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers [published online ahead of print January 19, 2012]. Ann Surg Oncol. doi: 10.1245/s10434-011-2198-x
30. Gholami S, Antonacci C, Carew A, et al. Vaccinia virus GLV-1h153: effective novel treatment agent & imaging tool for the detection of positive surgical margins of triple-negative breast cancer. Acad Surg Congr. 2012.